Home › Companies › Bio-Rad Laboratories, Inc. › 2025-2026

Bio-Rad Laboratories, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

13Reported items
456Asset managers
2,909Fund votes
2026-04-21Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Bio-Rad Laboratories, Inc. in the interactive database Compare manager voting policies

How asset managers voted at the Bio-Rad Laboratories, Inc. 2025-2026 meeting

Each item below shows how the 456 asset managers that disclosed a Bio-Rad Laboratories, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Bio-Rad Laboratories, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Advisory vote to approve executive compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

85% fund support · no official result

FOR 85%AGAINST 15%

The 436 asset managers below cast 85% of the shares they voted on this item FOR (16,041,232 for, 2,899,172 against).

FOR: 16,041,232 (84.6%)AGAINST: 2,899,172 (15.3%)ABSTAIN: 14,597 (0.1%)NOT VOTED: 311 (0.0%)

Largest asset managers voting on “Advisory vote to approve executive compensation.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Vote
First Eagle Investment Management, LLC	2,360,553	0	For
FIRST EAGLE FUNDS	1,957,181	0	For
Vanguard	1,787,196	1	For
BlackRock	1,265,807	951	For
Capital Group	1	1,214,042	Against
Parnassus	506,478	0	For
EARNEST PARTNERS LLC	163,973	329,131	Against
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	456,503	0	For
Dimensional	443,537	0	For
First Pacific Advisors, LP	400,789	0	For
State Street	387,415	4,805	For
ARIEL INVESTMENT TRUST	388,191	0	For
Charles Schwab	366,584	0	For
UBS	0	347,990	Against
GEODE CAPITAL MANAGEMENT, LLC	340,465	0	For
Capital Research Global Investors	0	314,042	Against
Fidelity	309,493	2,435	For
MFS	288,710	0	For
John Hancock	262,807	0	For
Investment Managers Series Trust III	259,106	0	For
ARIEL INVESTMENTS, LLC	244,343	0	For
T. Rowe Price	208,363	0	For
Allspring	203,774	0	For
Mawer Investment Management Ltd.	0	201,944	Against
Putnam	195,754	0	For

Showing the 25 largest of 436 asset managers. See all 436 in the interactive database.

2. Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.

COMPENSATION

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.8%

The 119 asset managers below cast 99.9% of the shares they voted on this item FOR (8,523,552 for, 609 against).

FOR: 8,523,552 (99.9%)AGAINST: 609 (0.0%)ABSTAIN: 10,532 (0.1%)NOT VOTED: 14 (0.0%)

Largest asset managers voting on “Approval of the Amended Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Vote
FIRST EAGLE FUNDS	1,957,181	0	For
Vanguard	1,645,001	1	For
Capital Group	764,042	0	For
BlackRock	748,911	0	For
ARIEL INVESTMENT TRUST	388,191	0	For
Dimensional	347,667	0	For
Fidelity	309,682	0	For
MFS	288,710	0	For
Investment Managers Series Trust III	259,106	0	For
Parnassus	253,239	0	For
LONGLEAF PARTNERS FUNDS TRUST	185,868	0	For
Charles Schwab	182,811	0	For
John Hancock	135,145	0	For
Allspring	94,470	0	For
PIMCO	88,186	0	For
T. Rowe Price	80,749	0	For
Putnam	80,552	0	For
Transamerica	65,692	0	For
TRUST FOR PROFESSIONAL MANAGERS	64,977	0	For
Equitable	47,104	0	For
RBB Fund Trust	46,762	0	For
BOSTON TRUST WALDEN FUNDS	38,293	0	For
Jackson National	36,655	0	For
FRANKLIN VALUE INVESTORS TRUST	34,773	0	For
TIAA	26,327	0	For

Showing the 25 largest of 119 asset managers. See all 119 in the interactive database.

3. Nominees: Arnold A. Pinkston

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

90% fund support · no official result

FOR 90%10%

The 116 asset managers below cast 90% of the shares they voted on this item FOR (7,704,628 for, 828,809 against).

FOR: 7,704,628 (90.3%)AGAINST: 828,809 (9.7%)ABSTAIN: 2,872 (0.0%)NOT VOTED: 14 (0.0%)

Largest asset managers voting on “Nominees: Arnold A. Pinkston” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Vote
FIRST EAGLE FUNDS	1,957,181	0	For
Vanguard	1,644,196	806	For
Capital Group	764,042	0	For
BlackRock	748,911	0	For
ARIEL INVESTMENT TRUST	388,191	0	For
Dimensional	347,667	0	For
Fidelity	35,004	274,678	Against
MFS	288,710	0	For
Investment Managers Series Trust III	259,106	0	For
Parnassus	0	253,239	Against
LONGLEAF PARTNERS FUNDS TRUST	185,868	0	For
Charles Schwab	182,780	31	For
John Hancock	133,408	1,737	For
Allspring	94,470	0	For
PIMCO	88,186	0	For
T. Rowe Price	0	80,749	Against
Putnam	0	80,552	Against
Transamerica	65,692	0	For
TRUST FOR PROFESSIONAL MANAGERS	64,977	0	For
Equitable	26,490	20,614	For
RBB Fund Trust	46,762	0	For
BOSTON TRUST WALDEN FUNDS	0	38,293	Against
Jackson National	36,655	0	For
FRANKLIN VALUE INVESTORS TRUST	0	34,773	Against
TIAA	26,327	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

4. Nominees: Melinda Litherland

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

90% fund support · no official result

FOR 90%10%

The 116 asset managers below cast 90% of the shares they voted on this item FOR (7,704,280 for, 829,157 against).

FOR: 7,704,280 (90.3%)AGAINST: 829,157 (9.7%)ABSTAIN: 2,872 (0.0%)NOT VOTED: 14 (0.0%)

Largest asset managers voting on “Nominees: Melinda Litherland” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Vote
FIRST EAGLE FUNDS	1,957,181	0	For
Vanguard	1,644,196	806	For
Capital Group	764,042	0	For
BlackRock	748,911	0	For
ARIEL INVESTMENT TRUST	388,191	0	For
Dimensional	347,667	0	For
Fidelity	35,004	274,678	Against
MFS	288,710	0	For
Investment Managers Series Trust III	259,106	0	For
Parnassus	0	253,239	Against
LONGLEAF PARTNERS FUNDS TRUST	185,868	0	For
Charles Schwab	182,780	31	For
John Hancock	133,408	1,737	For
Allspring	94,470	0	For
PIMCO	88,186	0	For
T. Rowe Price	0	80,749	Against
Putnam	0	80,552	Against
Transamerica	65,692	0	For
TRUST FOR PROFESSIONAL MANAGERS	64,977	0	For
Equitable	26,490	20,614	For
RBB Fund Trust	46,762	0	For
BOSTON TRUST WALDEN FUNDS	0	38,293	Against
Jackson National	36,655	0	For
FRANKLIN VALUE INVESTORS TRUST	0	34,773	Against
TIAA	26,327	0	For

Showing the 25 largest of 116 asset managers. See all 116 in the interactive database.

5. Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 114 asset managers below cast 99.9% of the shares they voted on this item FOR (8,516,716 for, 608 against).

FOR: 8,516,716 (100.0%)AGAINST: 608 (0.0%)ABSTAIN: 2,872 (0.0%)NOT VOTED: 14 (0.0%)

Largest asset managers voting on “Proposal to ratify the selection of KPMG LLP to serve as the Company's independent auditors.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Vote
FIRST EAGLE FUNDS	1,957,181	For
Vanguard	1,645,001	For
Capital Group	764,042	For
BlackRock	748,911	For
ARIEL INVESTMENT TRUST	388,191	For
Dimensional	347,667	For
Fidelity	309,682	For
MFS	288,710	For
Investment Managers Series Trust III	259,106	For
Parnassus	253,239	For
LONGLEAF PARTNERS FUNDS TRUST	185,868	For
Charles Schwab	182,811	For
John Hancock	135,145	For
Allspring	94,470	For
PIMCO	88,186	For
T. Rowe Price	80,749	For
Putnam	80,552	For
Transamerica	65,692	For
TRUST FOR PROFESSIONAL MANAGERS	64,977	For
Equitable	47,104	For
RBB Fund Trust	46,762	For
BOSTON TRUST WALDEN FUNDS	38,293	For
Jackson National	36,655	For
FRANKLIN VALUE INVESTORS TRUST	34,773	For
TIAA	26,327	For

Showing the 25 largest of 114 asset managers. See all 114 in the interactive database.

6. Stockholder proposal regarding dual class capital structure.

SHAREHOLDER RIGHTS AND DEFENSES

Combines 2 wordings of this item as funds reported it.

92% fund support · no official result

FOR 92%8%

The 113 asset managers below cast 92% of the shares they voted on this item FOR (7,818,748 for, 698,477 against).

FOR: 7,818,748 (91.8%)AGAINST: 698,477 (8.2%)ABSTAIN: 2,872 (0.0%)NOT VOTED: 14 (0.0%)

Largest asset managers voting on “Stockholder proposal regarding dual class capital structure.” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Vote
FIRST EAGLE FUNDS	1,957,181	0	For
Vanguard	1,627,416	17,586	For
Capital Group	764,042	0	For
BlackRock	748,911	0	For
ARIEL INVESTMENT TRUST	0	388,191	Against
Dimensional	347,667	0	For
Fidelity	309,682	0	For
MFS	288,710	0	For
Investment Managers Series Trust III	0	259,106	Against
Parnassus	253,239	0	For
LONGLEAF PARTNERS FUNDS TRUST	185,868	0	For
Charles Schwab	182,722	89	For
John Hancock	135,145	0	For
Allspring	94,470	0	For
PIMCO	88,186	0	For
T. Rowe Price	80,749	0	For
Putnam	80,552	0	For
Transamerica	65,692	0	For
TRUST FOR PROFESSIONAL MANAGERS	64,977	0	For
Equitable	27,104	20,000	For
RBB Fund Trust	46,762	0	For
BOSTON TRUST WALDEN FUNDS	38,293	0	For
Jackson National	34,200	2,455	For
FRANKLIN VALUE INVESTORS TRUST	34,773	0	For
TIAA	26,327	0	For

Showing the 25 largest of 113 asset managers. See all 113 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

97% fund support · no official result

FOR 96%

The 10 asset managers below cast 97% of the shares they voted on this item FOR (257,260 for, 7,489 against).

FOR: 257,260 (96.3%)AGAINST: 7,489 (2.8%)ABSTAIN: 2,381 (0.9%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
SOUTHEASTERN ASSET MANAGEMENT INC/TN/	217,891	0	0	For
SECTOR GAMMA AS	18,752	0	0	For
Hosking Partners LLP	10,419	0	0	For
Empower	8,473	0	0	For
GreenFi Funds Trust	0	7,489	0	Against
MANGROVE PARTNERS IM, LLC	0	0	2,381	Abstain
APG Asset Management US Inc.	1,323	0	0	For
NORTHERN LIGHTS FUND TRUST II	400	0	0	For
Colony Family Offices, LLC	2	0	0	For
Dixon Mitchell Investment Counsel Inc.	0	0	0	--

8. Amend Omnibus Stock Plan

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (16,362 for, 0 against).

FOR: 16,362 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Vote
Empower	8,473	For
GreenFi Funds Trust	7,489	For
NORTHERN LIGHTS FUND TRUST II	400	For
Dixon Mitchell Investment Counsel Inc.	0	--

9. Approve Recapitalization Plan for all Stock to Have One-vote per Share

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (16,362 for, 0 against).

FOR: 16,362 (100.0%)

Largest asset managers voting on “Approve Recapitalization Plan for all Stock to Have One-vote per Share” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Vote
Empower	8,473	For
GreenFi Funds Trust	7,489	For
NORTHERN LIGHTS FUND TRUST II	400	For
Dixon Mitchell Investment Counsel Inc.	0	--

10. Ratify KPMG LLP as Auditors

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (16,362 for, 0 against).

FOR: 16,362 (100.0%)

Largest asset managers voting on “Ratify KPMG LLP as Auditors” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Vote
Empower	8,473	For
GreenFi Funds Trust	7,489	For
NORTHERN LIGHTS FUND TRUST II	400	For
Dixon Mitchell Investment Counsel Inc.	0	--

11. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 99.2%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (914 for, 0 against).

FOR: 914 (99.2%)ABSTAIN: 7 (0.8%)

Largest asset managers voting on “14A Executive Compensation” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Claret Asset Management Corp	914	0	0	0	For
LEAVELL INVESTMENT MANAGEMENT, INC.	0	0	7	0	Abstain

12. An Advisory (Non-Binding) Vote to approve Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 85%NOT VOTED 15%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (83,732 for, 0 against).

FOR: 83,732 (84.7%)NOT VOTED: 15,173 (15.3%)

Largest asset managers voting on “An Advisory (Non-Binding) Vote to approve Executive Compensation” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
QVIDTVM Management LLC	83,732	0	0	0	For
National Philanthropic Trust	0	0	0	0	Not Voted

13. To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (4 for, 0 against).

FOR: 4 (100.0%)

Largest asset managers voting on “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” at Bio-Rad Laboratories, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Modern Wealth Management, LLC	2	0	0	0	For
Tandem Financial, LLC	2	0	0	0	For

Largest Bio-Rad Laboratories, Inc. shareholders voting in 2025-2026

Ranked by the number of Bio-Rad Laboratories, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 26,958,000 shares outstanding at the time of that meeting.

Top Bio-Rad Laboratories, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	First Eagle Investment Management, LLC	8.76%
2	FIRST EAGLE FUNDS	7.26%
3	Vanguard	6.63%
4	BlackRock	4.70%
5	Capital Group	4.50%
6	Parnassus	1.88%
7	EARNEST PARTNERS LLC	1.83%
8	MASSACHUSETTS FINANCIAL SERVICES CO /MA/	1.69%
9	Dimensional	1.65%
10	First Pacific Advisors, LP	1.49%

Reported Bio-Rad Laboratories, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Bio-Rad Laboratories, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	6.58%	13F
BlackRock	6.23%	13F
Dimensional Fund Advisors	4.04%	13F
State Street	2.08%	13F
Geode Capital	1.35%	13F
Northern Trust	0.81%	13F
Charles Schwab	0.73%	13F
Morgan Stanley	0.69%	13F
Franklin Templeton	0.63%	13F
Citadel Advisors	0.56%	13F

Percentages above are of 26,958,000 shares outstanding, as reported by Bio-Rad Laboratories, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Bio-Rad Laboratories, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Bio-Rad Laboratories, Inc.'s shareholder meeting held 2026-04-21, in the 2025-2026 proxy season, 456 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,909 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — Advisory vote to approve executive compensation. — the reporting funds cast 85% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Bio-Rad Laboratories, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).